These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
158 related articles for article (PubMed ID: 21744129)
1. Phenotype-dependent production of des-γ-carboxy prothrombin in hepatocellular carcinoma. Suzuki H; Murata K; Gotoh T; Kusano M; Okano H; Oyamada T; Yasuda Y; Imamura M; Kudo M; Mizokami M; Sakamoto A J Gastroenterol; 2011 Oct; 46(10):1219-29. PubMed ID: 21744129 [TBL] [Abstract][Full Text] [Related]
2. Cytoskeletal changes during epithelial-to-fibroblastoid conversion as a crucial mechanism of des-gamma-carboxy prothrombin production in hepatocellular carcinoma. Murata K; Suzuki H; Okano H; Oyamada T; Yasuda Y; Sakamoto A Int J Oncol; 2009 Nov; 35(5):1005-14. PubMed ID: 19787254 [TBL] [Abstract][Full Text] [Related]
3. Hypoxia-induced des-gamma-carboxy prothrombin production in hepatocellular carcinoma. Murata K; Suzuki H; Okano H; Oyamada T; Yasuda Y; Sakamoto A Int J Oncol; 2010 Jan; 36(1):161-70. PubMed ID: 19956845 [TBL] [Abstract][Full Text] [Related]
4. Impairment of clathrin-mediated endocytosis via cytoskeletal change by epithelial to fibroblastoid conversion in HepG2 cells: a possible mechanism of des-gamma-carboxy prothrombin production in hepatocellular carcinoma. Murata K; Sakamoto A Int J Oncol; 2008 Dec; 33(6):1149-55. PubMed ID: 19020747 [TBL] [Abstract][Full Text] [Related]
5. Association of des-γ-carboxy prothrombin production and Sonazoid-enhanced ultrasound findings in hepatocellular carcinomas of different histologic grades. Murata K; Saito A; Katagiri S; Ariizumi S; Nakano M; Yamamoto M J Med Ultrason (2001); 2018 Apr; 45(2):223-229. PubMed ID: 28828695 [TBL] [Abstract][Full Text] [Related]
6. Levels of vitamin K, immunoreactive prothrombin, des-gamma-carboxy prothrombin and gamma-glutamyl carboxylase activity in hepatocellular carcinoma tissue. Yamagata H; Nakanishi T; Furukawa M; Okuda H; Obata H J Gastroenterol Hepatol; 1995; 10(1):8-13. PubMed ID: 7620113 [TBL] [Abstract][Full Text] [Related]
7. Hypoxia Accelerates Aggressiveness of Hepatocellular Carcinoma Cells Involving Oxidative Stress, Epithelial-Mesenchymal Transition and Non-Canonical Hedgehog Signaling. Liu Z; Tu K; Wang Y; Yao B; Li Q; Wang L; Dou C; Liu Q; Zheng X Cell Physiol Biochem; 2017; 44(5):1856-1868. PubMed ID: 29237157 [TBL] [Abstract][Full Text] [Related]
8. Vitamin K2 inhibits the growth of hepatocellular carcinoma via decrease of des-gamma-carboxy prothrombin. Ma M; Qu XJ; Mu GY; Chen MH; Cheng YN; Kokudo N; Tang W; Cui SX Chemotherapy; 2009; 55(1):28-35. PubMed ID: 18974646 [TBL] [Abstract][Full Text] [Related]
9. Des-gamma-carboxy prothrombin antagonizes the effects of Sorafenib on human hepatocellular carcinoma through activation of the Raf/MEK/ERK and PI3K/Akt/mTOR signaling pathways. Cui SX; Shi WN; Song ZY; Wang SQ; Yu XF; Gao ZH; Qu XJ Oncotarget; 2016 Jun; 7(24):36767-36782. PubMed ID: 27167344 [TBL] [Abstract][Full Text] [Related]
10. Des-gamma-carboxy prothrombin (DCP) antagonizes the effects of gefitinib on human hepatocellular carcinoma cells. Cui SX; Zhang YS; Chu JH; Song ZY; Qu XJ Cell Physiol Biochem; 2015; 35(1):201-12. PubMed ID: 25591763 [TBL] [Abstract][Full Text] [Related]
11. Poly-(ADP-Ribose) Polymerase-1 Promotes Prothrombin Gene Transcription and Produces Des-Gamma-Carboxy Prothrombin in Hepatocellular Carcinoma. Taniguchi T; Kishi K; Nakagawa T; Tanaka H; Tanaka T; Tomonari T; Okamoto K; Sogabe M; Miyamoto H; Okahisa T; Muguruma N; Kajimoto M; Sagawa I; Takayama T Digestion; 2017; 95(3):242-251. PubMed ID: 28384634 [TBL] [Abstract][Full Text] [Related]
12. Production of abnormal prothrombin (des-gamma-carboxy prothrombin) by hepatocellular carcinoma. A clinical and experimental study. Okuda H; Obata H; Nakanishi T; Furukawa R; Hashimoto E J Hepatol; 1987 Jun; 4(3):357-63. PubMed ID: 3036940 [TBL] [Abstract][Full Text] [Related]
13. Prognostic and diagnostic value of des-γ-carboxy prothrombin in liver cancer. Bertino G; Ardiri AM; Calvagno GS; Bertino N; Boemi PM Drug News Perspect; 2010 Oct; 23(8):498-508. PubMed ID: 21031166 [TBL] [Abstract][Full Text] [Related]
15. Clinicopathologic features of patients with hepatocellular carcinoma seropositive for alpha-fetoprotein-L3 and seronegative for des-gamma-carboxy prothrombin in comparison with those seropositive for des-gamma-carboxy prothrombin alone. Okuda H; Nakanishi T; Takatsu K; Saito A; Hayashi N; Yamamoto M; Takasaki K; Nakano M J Gastroenterol Hepatol; 2002 Jul; 17(7):772-8. PubMed ID: 12121507 [TBL] [Abstract][Full Text] [Related]
16. Plasma abnormal prothrombin (des-gamma-carboxy prothrombin) as a marker of hepatocellular carcinoma. Fujiyama S; Morishita T; Hashiguchi O; Sato T Cancer; 1988 Apr; 61(8):1621-8. PubMed ID: 2450634 [TBL] [Abstract][Full Text] [Related]
17. Significance of des-gamma-carboxy prothrombin production in hepatocellular carcinoma. Fujikawa T; Shiraha H; Yamamoto K Acta Med Okayama; 2009 Dec; 63(6):299-304. PubMed ID: 20035286 [TBL] [Abstract][Full Text] [Related]
18. Wnt/β-catenin signaling enhances hypoxia-induced epithelial-mesenchymal transition in hepatocellular carcinoma via crosstalk with hif-1α signaling. Zhang Q; Bai X; Chen W; Ma T; Hu Q; Liang C; Xie S; Chen C; Hu L; Xu S; Liang T Carcinogenesis; 2013 May; 34(5):962-73. PubMed ID: 23358852 [TBL] [Abstract][Full Text] [Related]
19. Exon 2 deletion splice variant of gamma-glutamyl carboxylase causes des-gamma-carboxy prothrombin production in hepatocellular carcinoma cell lines. Ueda N; Shiraha H; Fujikawa T; Takaoka N; Nakanishi Y; Suzuki M; Matsuo N; Tanaka S; Nishina S; Uemura M; Takaki A; Shiratori Y; Yamamoto K Mol Oncol; 2008 Oct; 2(3):241-9. PubMed ID: 19383345 [TBL] [Abstract][Full Text] [Related]
20. Des-gamma-carboxy prothrombin increases the expression of angiogenic factors in human hepatocellular carcinoma cells. Gao FJ; Cui SX; Chen MH; Cheng YN; Sun LR; Ward SG; Kokudo N; Tang W; Qu XJ Life Sci; 2008 Dec; 83(23-24):815-20. PubMed ID: 18976674 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]